Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.

The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).

The majority of emergency room visits can be averted with a call or visit to a pediatrician